The development of triple agonists for obesity has built upon successes of several dual combinations of entero-pancreatic hormone receptor agonists, in particular, GLP-1/GIP dual agonists and GLP-1/GCG dual agonists. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.